Movatterモバイル変換


[0]ホーム

URL:


SG11201807885PA - Compositions and methods for making antibodies based on use of expression-enhancing loci - Google Patents

Compositions and methods for making antibodies based on use of expression-enhancing loci

Info

Publication number
SG11201807885PA
SG11201807885PASG11201807885PASG11201807885PASG11201807885PASG 11201807885P ASG11201807885P ASG 11201807885PASG 11201807885P ASG11201807885P ASG 11201807885PASG 11201807885P ASG11201807885P ASG 11201807885PASG 11201807885P ASG11201807885P ASG 11201807885PA
Authority
SG
Singapore
Prior art keywords
international
rule
tarrytown
saw mill
expression
Prior art date
Application number
SG11201807885PA
Inventor
Robert Babb
Darya Burakov
Gang Chen
James Fandl
Yu Zhao
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of SG11201807885PApublicationCriticalpatent/SG11201807885PA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 Iiv 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/184832 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07K 16/00 (2006.01) C12N 15/90 (2006.01) KM, ML, MR, NE, SN, TD, TG). CO7K 16/46 (2006.01) (21) International Application Number: Declarations under Rule 4.17: PCT/US2017/028555 — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 20 April 2017 (20.04.2017) earlier application (Rule 4.17(iii)) — of inventorship (Rule 4.17(iv)) (25) Filing Language: English (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: — with sequence listing part of description (Rule 5.2(a)) 62/325,400 20 April 2016 (20.04.2016) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). (72) Inventors: BABB, Robert; c/o Regeneron Pharmaceu- ticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). BURAKOV, Darya; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar- rytown, NY 10591-6707 (US). CHEN, Gang; c/o Regen- eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). FANDL, James, P.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). = — (74) Agent: GROLZ, Edward, W.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY 11530 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, - TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, .4 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, N i MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, M co iv co 1-1 (54) Title: COMPOSITIONS AND METHODS FOR MAKING ANTIBODIES BASED ON USE OF EXPRESSION-ENHANCING IN LOCI 11 0 (57) : This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In partic- \" ular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific C and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expres- sion-enhancing locus.
SG11201807885PA2016-04-202017-04-20Compositions and methods for making antibodies based on use of expression-enhancing lociSG11201807885PA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201662325400P2016-04-202016-04-20
PCT/US2017/028555WO2017184832A1 (en)2016-04-202017-04-20Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (1)

Publication NumberPublication Date
SG11201807885PAtrue SG11201807885PA (en)2018-10-30

Family

ID=58701851

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10202010155YASG10202010155YA (en)2016-04-202017-04-20Compositions and methods for making antibodies based on use of expression-enhancing loci
SG11201807885PASG11201807885PA (en)2016-04-202017-04-20Compositions and methods for making antibodies based on use of expression-enhancing loci

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG10202010155YASG10202010155YA (en)2016-04-202017-04-20Compositions and methods for making antibodies based on use of expression-enhancing loci

Country Status (15)

CountryLink
US (2)US11512144B2 (en)
EP (1)EP3445781A1 (en)
JP (3)JP7096770B2 (en)
KR (2)KR20230098361A (en)
CN (2)CN109195986B (en)
AR (1)AR109451A1 (en)
AU (2)AU2017253241B2 (en)
BR (1)BR112018071283A2 (en)
CA (1)CA3015389A1 (en)
EA (1)EA201892010A1 (en)
IL (2)IL314779A (en)
MX (1)MX2018012868A (en)
SG (2)SG10202010155YA (en)
TW (2)TWI827531B (en)
WO (1)WO2017184832A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SG10202010155YA (en)*2016-04-202020-11-27Regeneron PharmaCompositions and methods for making antibodies based on use of expression-enhancing loci
CN111886244A (en)*2017-12-222020-11-03豪夫迈·罗氏有限公司 Targeted integration of nucleic acids
CA3123448A1 (en)*2018-12-212020-06-25Genentech, Inc.Targeted integration of nucleic acids
SG11202110076PA (en)*2019-04-022021-10-28Chugai Pharmaceutical Co LtdMethod of introducing target-specific foreign gene
CN114080454A (en)2019-06-262022-02-22豪夫迈·罗氏有限公司Randomized configurational targeted integration of nucleic acids
IL312124A (en)2021-10-182024-06-01Regeneron PharmaEukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202334402A (en)2021-10-182023-09-01美商再生元醫藥公司Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
IL312148A (en)2021-10-182024-06-01Regeneron PharmaControlled transcription of polynucleotides
KR20240117146A (en)*2021-12-222024-07-31제넨테크, 인크. Multiple vector recombinase-mediated cassette exchange
JPWO2023238949A1 (en)*2022-06-102023-12-14
WO2025054526A1 (en)2023-09-072025-03-13Regeneron Pharmaceuticals, Inc.Production and purification of covalently surface modified adeno-associated virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4634665A (en)1980-02-251987-01-06The Trustees Of Columbia University In The City Of New YorkProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en)1982-01-111987-04-07Board Of Trustees Of Leland Stanford Jr. UniversityGene amplification in eukaryotic cells
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en)1998-09-222004-10-05Bristol-Myers Squibb CompanyExpression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en)2000-06-232002-06-18Genetastix CorporationHigh throughput generation and screening of fully human antibody repertoire in yeast
CA2485939C (en)2002-05-292013-10-29Regeneron Pharmaceuticals, Inc.Inducible eukaryotic expression system
US20050019925A1 (en)2002-11-142005-01-27Genentech, Inc.Intron fusion construct and method of using for selecting high-expressing production cell lines
JP5620626B2 (en)2005-03-312014-11-05中外製薬株式会社 Polypeptide production method by association control
AU2007229698B9 (en)2006-03-242012-11-08Merck Patent GmbhEngineered heterodimeric protein domains
MY147468A (en)2006-06-022012-12-14Regeneron PharmaHigh affinity antibodies to human il-6 receptor
JP2010514416A (en)2006-12-212010-05-06グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New method
US20080216185A1 (en)2007-01-192008-09-04Invitrogen CorporationCompositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
ES2593484T3 (en)2007-03-292016-12-09Genmab A/S Bispecific antibodies and their production methods
WO2008151219A1 (en)*2007-06-042008-12-11Regeneron Pharmaceuticals, Inc.Enhanced expression and stability regions
DK2235064T3 (en)2008-01-072016-01-11Amgen IncA process for the preparation of heterodimeric Fc molecules using electrostatic control effects
CA2764370C (en)*2009-06-022018-08-21Regeneron Pharmaceuticals, Inc.Fucosylation-deficient cells
KR20120027055A (en)2009-06-262012-03-20리제네론 파라마큐티칼스 인코포레이티드Readily isolated bispecific antibodies with native immunoglobulin format
AU2010296018B2 (en)2009-09-162016-05-05Genentech, Inc.Coiled coil and/or tether containing protein complexes and uses thereof
KR20120099376A (en)*2009-09-182012-09-10셀렉시스 에스. 에이.Products and methods for enhanced transgene expression and processing
EA201201435A1 (en)2010-04-202013-04-30Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
PL2606064T3 (en)2010-08-162015-07-31Novimmune SaMethods for the generation of multispecific and multivalent antibodies
TW201823460A (en)2012-05-292018-07-01美商再生元醫藥公司Production cell line enhancers
EP2711428A1 (en)2012-09-212014-03-26Lonza Biologics plc.Site-specific integration
US20150203591A1 (en)*2012-08-022015-07-23Regeneron Pharmaceuticals, Inc.Mutivalent antigen-binding proteins
JOP20200236A1 (en)2012-09-212017-06-16Regeneron PharmaAnti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI745610B (en)2012-11-142021-11-11美商再生元醫藥公司Recombinant cell surface capture proteins
TWI635098B (en)2013-02-012018-09-11再生元醫藥公司Antibodies comprising chimeric constant domains
US20140308285A1 (en)2013-03-152014-10-16Amgen Inc.Heterodimeric bispecific antibodies
TWI670283B (en)2013-12-232019-09-01美商建南德克公司Antibodies and methods of use
TWI701042B (en)2014-03-192020-08-11美商再生元醫藥公司Methods and antibody compositions for tumor treatment
SG11201703149RA (en)2014-10-232018-02-27Regeneron PharmaNovel cho integration sites and uses thereof
MY195059A (en)2015-09-232023-01-05Regeneron PharmaOptimized Anti-CD3 Bispecific Antibodies and Uses Thereof
SG10202010155YA (en)*2016-04-202020-11-27Regeneron PharmaCompositions and methods for making antibodies based on use of expression-enhancing loci

Also Published As

Publication numberPublication date
US20190233544A1 (en)2019-08-01
US11512144B2 (en)2022-11-29
EA201892010A1 (en)2019-03-29
MX2018012868A (en)2019-03-11
CN116515757A (en)2023-08-01
KR20180134893A (en)2018-12-19
IL314779A (en)2024-10-01
TWI827531B (en)2024-01-01
CA3015389A1 (en)2017-10-26
CN109195986B (en)2023-01-03
US20230130799A1 (en)2023-04-27
IL262266B1 (en)2024-09-01
SG10202010155YA (en)2020-11-27
IL262266B2 (en)2025-01-01
JP2019515666A (en)2019-06-13
JP7096770B2 (en)2022-07-06
BR112018071283A2 (en)2019-02-12
KR20230098361A (en)2023-07-03
CN109195986A (en)2019-01-11
WO2017184832A1 (en)2017-10-26
KR102547738B1 (en)2023-06-26
AU2017253241A1 (en)2018-09-20
AU2017253241B2 (en)2024-07-04
JP2021164479A (en)2021-10-14
AU2024220124A1 (en)2024-10-17
TW201803986A (en)2018-02-01
JP2024023449A (en)2024-02-21
AR109451A1 (en)2018-12-12
EP3445781A1 (en)2019-02-27
IL262266A (en)2018-11-29
TW202415767A (en)2024-04-16

Similar Documents

PublicationPublication DateTitle
SG11201807885PA (en)Compositions and methods for making antibodies based on use of expression-enhancing loci
SG11201807881VA (en)Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201909203WA (en)Tissue selective transgene expression
SG11201810327XA (en)Single domain serum albumin binding protein
SG11201807187XA (en)Binding members to pd-l1
SG11201900201YA (en)Methods for quantitating individual antibodies from a mixture
SG11202000073XA (en)Anti-cd8 antibodies and uses thereof
SG11201808622SA (en)Chimeric receptors to flt3 and methods of use thereof
SG11201909941QA (en)Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201906341XA (en)Improved serum albumin binders
SG11201811270WA (en)Systems and methods for trajectory determination
SG11201910027YA (en)Bispecific antibody against ox40 and ctla-4
SG11201909432SA (en)Compounds for increasing genome editing efficiency
SG11201807794VA (en)Naphthene-containing distillate stream compositions and uses thereof
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903830TA (en)Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201909011PA (en)Niraparib compositions
SG11201808398PA (en)Cell line for recombinant protein and/or viral vector production
SG11201810777WA (en)Purification of multispecific antibodies
SG11201900772YA (en)Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201908784TA (en)Improved antigen binding receptor formats
SG11201808476SA (en)Recycling of polymer matrix composite
SG11201805950UA (en)Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201809793UA (en)Tl1a antibodies and uses thereof
SG11201807474SA (en)Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

[8]ページ先頭

©2009-2025 Movatter.jp